个人简介

麻楠，研究员。2011年6月毕业于中国药科大学，获学士学位；2016年6月获中国药科大学药物化学博士学位（硕博连读，与中国科学院广州生物医药与健康研究院联合培养）；2016年7月-2019年12月于暨南大学药学院从事博士后科研工作；2020年1月-2021年7月于中国中医科学院青蒿素研究中心任副研究员；2021年9月起任暨南大学研究员、硕士生导师。担任Molecules期刊客座编辑、Chemical Biology & Drug Design等期刊审稿人，兼任中国研究型医院学会神经再生与修复专业委员会委员。

近年来主要从事化学生物学交叉学科领域研究，基于前期天然产物有机全合成及药物化学（抗肿瘤及抗AD候选药物分子的设计合成）研究经历、利用化学蛋白质组学技术开展药物活性分子靶标识别、靶蛋白氨基酸残基结合位点鉴定等研究工作。已在Lancet、JACS、Angew Chem Int Ed等领域顶尖期刊发表SCI论文20余篇（累积影响因子>400），参编英文论著1篇。其中以第一/通讯作者（含共同）在JACS、Angew Chem Int Ed、Signal Transduct Taget Ther等期刊发表论文13篇（IF>10的7篇，被Nat Chem、Pharmacol Rev、Acc Chem Res、Chem Soc Rev等国际期刊引用700余次）。应Pharmacol Ther、Nat Prod Rep及Lancet杂志邀请，分别作为第一作者、共同第一作者及共同作者与诺贝尔奖获得者屠呦呦研究员共同撰写青蒿素相关论文3篇。申请中国发明专利6项，其中4项获授权。主持国家自然科学基金项目2项、省部级及其他科研项目4项，作为主要成员参与国家自然科学基金等项目4项。

研究方向

药物化学生物学—药物尤其是天然药物的可药性靶标发现与确证研究；靶蛋白氨基酸残基位点修饰研究

药物化学--中药及天然药物来源的创新药物研究 

代表性论文

1.Ke Cheng, Junyang Qi, Xiaojie Ren, Jie Zhang, Huangxu Li, Hanyue Xiao, Rui Wang, Zhiyang Liu, Lingkuan Meng, Nan Ma*, Hongyan Sun*. Developing Isoxazole as a Native Photo-Cross-Linker for Photoaffinity Labeling and Chemoproteomics. Angew Chem Int Ed Engl, 2022, 21, 61(47): e202209947. (IF: 16.6)

2.Nan Ma, Jun Hu, Zhimin Zhang, Wenyan Liu, Minhao Huang, Youlong Fan, Xingfeng Yin, Jiang Wang*, Ke Ding*, Wencai Ye*, Zhengqiu Li*. 2H-Azirine-based Reagents for Chemoselective Bioconjugation at Carboxyl Residues inside Live Cells. J Am Chem Soc, 2020, 142(13): 6051–6059. (IF: 15.0)

3.Xiao Chen#, Yutong Wang#, Nan Ma#, Jing Tian, Yurou Shao, Bo Zhu, Yin Kwan Wong, Zhen Liang, Chang Zou, Jigang Wang*. Target identification of natural medicine with chemical proteomics approach: probe synthesis, target fishing and protein identification. Signal Transduct Target Ther, 2020, 5(1): 72. (IF: 39.3)

4.Nan Ma, Ziyue Zhang, Fulong Liao, Tingliang Jiang, Youyou Tu*. The birth of artemisinin. Pharmacol Ther, 2020, 216: 107658. (IF: 13.5)

5.Hai-Ning Lyu#, Nan Ma#, Yuqing Meng#, Xing Zhang, Yin-Kwan Wong, Chengchao Xu*, Fulong Liao, Tingliang Jiang, Youyou Tu*, Jigang Wang*. Study towards improving artemisinin-based combination therapies. Nat Prod Rep, 2021, 38(7): 1243-1250. (IF: 11.9)

6.Shengnan Shen#, Qiwen Liao#, Ming Lyu#, Yin-Kwan Wong, Xing Zhang, Jing Zhou*, Nan Ma*, Jigang Wang*. The potential of artemisinins as anti-obesity agents via modulating the immune system. Pharmacol Ther, 2020, 216: 107696. (IF: 13.5)

7.Yuqing Meng#, Nan Ma#, Hai-Ning Lyu#, Yin Kwan Wong, Xing Zhang, Yongping Zhu, Peng Gao, Peng Sun, Yali Song, Lizhu Lin*, Jigang Wang*. Recent pharmacological advances in the repurposing of artemisinin drugs. Med Res Rev, 2021, 41(6): 3156–3181. (IF: 13.3)

8.Dandan Liu#, Piao Luo#, Liwei Gu, Qian Zhang, Peng Gao, Yongping Zhu, Xiao Chen, Qiuyan Guo, Junzhe Zhang, Nan Ma*, Jigang Wang*. Celastrol exerts a neuroprotective effect by directly binding to HMGB1 protein in cerebral ischemia-reperfusion. J Neuroinflamm, 2021, 18(1): 1–18. (IF: 9.6)

9.Nan Ma#, Yiwu Yao#, Bing-Xin Zhao, Ying Wang, Wen-Cai Ye*, Sheng Jiang*. Total synthesis of securinega alkaloids (-)-norsecurinine, (-)-niruroidine and (-)-flueggine A. Chem. Commun, 2014, 50: 9284–9287. (IF: 6.0)

10.Nan Ma, Zhi-Min Zhang, Jun-Seok Lee, Ke Cheng, Ligen Lin, Dong-Mei Zhang, Piliang Hao*, Ke Ding*, Wen-Cai Ye*, Zhengqiu Li*. Affinity-based Protein Profiling Reveals Cellular Targets of Photoreactive Anticancer Inhibitors. ACS Chem Biol, 2019, 14(12): 2546–2552. (IF: 4.6)

11.Genyun Tang#, Xin Liu#, Nan Ma#, Xiaojie Huang, Zhen-Long Wu, Wen Zhang, Ying Wang, Bing-Xin Zhao, Zhen-Ya Wang, Fanny C. F. Ip, Nancy Y. Ip*, Wen-Cai Ye*, Lei Shi*, Wei-Min Chen*. Design and synthesis of dimeric securinine analogues with neuritogenic activities. ACS Chem Neurosci, 2016, 7(10): 1442–1451. (IF = 5.7)

12.Nan Ma, Ying Wang, Bing-Xin Zhao, Wen-Cai Ye*, Sheng Jiang*. The application of click chemistry in the synthesis of agents with anticancer activity. Drug Des Dev Ther, 2015, 9: 1585–1599. (IF: 4.8) 

13.Nan Ma, Ying Luo, Ying Wang, Chenzhong Liao, Wen-Cai Ye*, Sheng Jiang*. Selective histone deacetylase inhibitors with anticancer activity. Curr Top Med Chem, 2016, 16(4): 415–426. (IF: 3.57) 

14.Jigang Wang, Chengchao Xu, Yin Kwan Wong, Nan Ma, Fulong Liao, Tingliang Jiang, Youyou Tu*. Triple artemisinin-based combination therapies for malaria: proceed with caution. Lancet, 2021, 396(10267): 1976. (IF: 202.7) 

15.Minfeng Chen, Xueping Lei, Changzheng Shi, Maohua Huang, Xiaobo Li, Baojian Wu, Zhengqiu Li, Weili Han, Bin Du, Jianyang Hu, Qiulin Nie, Weiqian Mai, Nan Ma, Nanhui Xu, Xinyi Zhang, Chunlin Fan, Aihua Hong, Minghan Xia, Liangping Luo, Ande Ma, Hongsheng Li, Qiang Yu, Heru Chen*, Dongmei Zhang*, Wencai Ye*. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents. J Clin Invest, 2017, 127(10): 3689-3701. (IF = 15.9)